Neuronal loss in the caudal intralaminar thalamic nuclei in a primate model of Parkinson's disease

Brain Structure and Function

Volumn 219, Issue 1, 2014, Pages 381-394

  Villalba, R M ^a   Wichmann, T ^a,b   Smith, Y ^a,b  

^a EMORY UNIVERSITY   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Centromedian; Monkey; MPTP; Parafascicular; Stereology; Thalamostriatal; Thalamus

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATTENTIONAL SET SHIFTING; CELL COUNT; CELL LOSS; COGNITION; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; HAPLORHINI; MOTOR ACTIVITY; NERVE CELL; NEURONAL LOSS; NEUROPATHOLOGY; NONHUMAN; OPTICAL DISSECTOR; OPTICS; PARKINSON DISEASE; PRIMATE MODEL; PRIORITY JOURNAL; STEREOLOGY; STRIATONIGRAL DEGENERATION; THALAMUS DORSOMEDIAL NUCLEUS; THALAMUS INTRALAMINAR NUCLEUS; THALAMUS NUCLEUS; THALAMUS PARAFASCICULAR NUCLEUS;

ANIMALIA; PARKINSONIA; PRIMATES;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ACETYLCHOLINESTERASE; ANIMALS; APOPTOSIS; CALBINDIN 1; CELL COUNT; DISEASE MODELS, ANIMAL; FEMALE; INTRALAMINAR THALAMIC NUCLEI; MACACA MULATTA; PARKINSONIAN DISORDERS; STEREOTAXIC TECHNIQUES; TYROSINE 3-MONOOXYGENASE;

EID: 84892369916     PISSN: 18632653     EISSN: 18632661     Source Type: Journal    
DOI: 10.1007/s00429-013-0507-9     Document Type: Article

References (96)

1. Aarsland D, Marsh L, Schrag A (2009) Neuropsychiatric symptoms in Parkinson's disease. Mov Disord 24:2175-2186
2. +): regional dopamine neuron uptake, toxicity, and novel rotational behavior following dopamine receptor proliferation. Eur J Pharmacol 131:199-209
3. Alvira D, Tajes M, Verdaguer E, de Arriba SG, Allgaier C, Matute C, Trullas R, Jimenez A, Pallas M, Camins A (2007) Inhibition of cyclin-dependent kinases is neuroprotective in 1-methyl-4-phenylpyridinium-induced apoptosis in neurons. Neuroscience 146:350-365
4. Aymerich MS, Barroso-Chinea P, Perez-Manso M, Munoz-Patino AM, Moreno-Igoa M, Gonzalez-Hernandez T, Lanciego JL (2006) Consequences of unilateral nigrostriatal denervation on the thalamostriatal pathway in rats. Eur J Neurosci 23:2099-2108
5. Bogenpohl JW, Galvan A, Hu X, Wichmann T, Smith Y (2012) Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex. Neuropharmacology. (In press), Corrected proof available online 22 May 2012
6. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E (2003) Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging 24:197-211
7. Brooks D, Halliday GM (2009) Intralaminar nuclei of the thalamus in Lewy body diseases. Brain Res Bull 78:97-104
8. Brown HD, Baker PM, Ragozzino ME (2010) The parafascicular thalamic nucleus concomitantly influences behavioral flexibility and dorsomedial striatal acetylcholine output in rats. J Neurosci 30:14390-14398
9. +) on mitochondrial membrane potential in cerebellar neurons: interaction with the NMDA receptor. J Neural Transm 104:569-577
10. Cools R, Barker RA, Sahakian BJ, Robbins TW (2001) Enhanced or impaired cognitive function in Parkinson's disease as a function of dopaminergic medication and task demands. Cereb Cortex 11:1136-1143
11. Ding JB, Guzman JN, Peterson JD, Goldberg JA, Surmeier DJ (2010) Thalamic gating of corticostriatal signaling by cholinergic interneurons. Neuron 67:294-307
12. Elgh E, Domellof M, Linder J, Edstrom M, Stenlund H, Forsgren L (2009) Cognitive function in early Parkinson's disease: a population-based study. Eur J Neurol 16:1278-1284
13. Foltynie T, Brayne CE, Robbins TW, Barker RA (2004) The cognitive ability of an incident cohort of Parkinson's patients in the UK. The CamPaIGN study. Brain 127:550-560
14. Fornai F, Bassi L, Bonaccorsi I, Giorgi F, Corsini GU (1997a) Noradrenaline loss selectivity exacerbates nigrostriatal toxicity in different species of rodents. Funct Neurol 12:193-198
15. + kinetics and MPTP-induced nigrostriatal dopamine depletions. J Pharmacol Exp Ther 283:100-107
16. Fornai F, Schluter OM, Lenzi P, Gesi M, Ruffoli R, Ferrucci M, Lazzeri G, Busceti CL, Pontarelli F, Battaglia G, Pellegrini A, Nicoletti F, Ruggieri S, Paparelli A, Sudhof TC (2005) Parkinson-like syndrome induced by continuous MPTP infusion: convergent roles of the ubiquitin-proteasome system and alpha-synuclein. Proc Natl Acad Sci USA 102:3413-3418
17. Fornai F, di Poggio AB, Pellegrini A, Ruggieri S, Paparelli A (2007) Noradrenaline in Parkinson's disease: from disease progression to current therapeutics. Curr Med Chem 14:2330-2334
18. Freyaldenhoven TE, Ali SF, Schmued LC (1997) Systemic administration of MPTP induces thalamic neuronal degeneration in mice. Brain Res 759:9-17
19. Gai WP, Halliday GM, Blumbergs PC, Geffen LB, Blessing WW (1991) Substance P-containing neurons in the mesopontine tegmentum are severely affected in Parkinson's disease. Brain 114:2253-2267
20. Galvan A, Smith Y (2011) The primate thalamostriatal system: anatomical organization, functional roles and possible involvement in Parkinson's disease. Basal Ganglia 1:179-189
21. Galvan A, Hu X, Smith Y, Wichmann T (2010) Localization and function of GABA transporters in the globus pallidus of parkinsonian monkeys. Exp Neurol 223:505-515
22. Gelb DJ, Oliver E, Gilman S (1999) Diagnostic criteria for Parkinson disease. Arch Neurol 56:33-39
23. Ghorayeb I, Fernagut PO, Hervier L, Labattu B, Bioulac B, Tison F (2002) A 'single toxin-double lesion' rat model of striatonigral degeneration by intrastriatal 1-methyl-4-phenylpyridinium ion injection: a motor behavioural analysis. Neuroscience 115:533-546
24. +: mechanism for its toxicity in cerebellar granule cells. Mol Neurobiol 30:253-264
25. Gundersen HJ, Osterby R (1981) Optimizing sampling efficiency of stereological studies in biology: or 'do more less well!'. J Microsc 121:65-73
26. Halliday GM (2009) Thalamic changes in Parkinson's disease. Parkinsonism Relat Dis 15(S3):S153-S155
27. Halliday GM, Gai WP, Blessing WW, Geffen LB (1990) Substance P-containing neurons in the pontomesencephalic tegmentum of the human brain. Neuroscience 39:81-96
28. Halliday GM, Macdonald V, Henderson JM (2005) A comparison of degeneration in motor thalamus and cortex between progressive supranuclear palsy and Parkinson's disease. Brain 128:2272-2280
29. Halliday G, Lees A, Stern M (2011) Milestones in Parkinson's disease-clinical and pathologic features. Mov Disord 26:1015-1021
30. Hantraye P, Varastet M, Peschanski M, Riche D, Cesaro P, Willner JC, Maziere M (1993) Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 53:169-178
31. +)-induced neurotoxicity in cerebellar granule neurons. Neurotox Res 19:374-388
32. Heinsen H, Rub U, Gangnus D, Jungkunz G, Bauer M, Ulmar G, Bethke B, Schuler M, Bocker F, Eisenmenger W, Gotz M, Strik M (1996) Nerve cell loss in the thalamic centromedian-parafascicular complex in patients with Huntington's disease. Acta Neuropathol 91:161-168
33. Henderson JM, Carpenter K, Cartwright H, Halliday GM (2000a) Loss of thalamic intralaminar nuclei in progressive supranuclear palsy and Parkinson's disease: clinical and therapeutic implications. Brain 123:1410-1421
34. Henderson JM, Carpenter K, Cartwright H, Halliday GM (2000b) Degeneration of the centre median-parafascicular complex in Parkinson's disease. Ann Neurol 47:345-352
35. Henderson JM, Schleimer SB, Allbutt H, Dabholkar V, Abela D, Jovic J, Quinlivan M (2005) Behavioural effects of parafascicular thalamic lesions in an animal model of parkinsonism. Behav Brain Res 162:222-232
36. + within the monoaminergic systems of the primate brain following MPTP administration: an in vivo autoradiographic study. Neuroscience 40:133-158
37. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F (1987) Neuronal loss in the pedunculopontine tegmental nucleus in Parkinson disease and in progressive supranuclear palsy. Proc Natl Acad Sci USA 84:5976-5980
38. Ilinsky IA, Kultas-Ilinsky K (2002) Motor thalamic circuits in primates with emphasis on the area targeted in treatments of movement disorders. Mov Disord 17(Suppl 3):S9-S14
39. Jellinger K (1988) The pedunculopontine nucleus in Parkinson's disease, progressive supranuclear palsy and Alzheimer's disease. J Neurol Neurosurg Psychiatry 51:540-543
40. +) within catecholaminergic neurons. Neurotoxicology 12:285-302
41. Jones EG (1985) The thalamus. Plenum Press, New York
42. Kato S, Kuramochi M, Kobayashi K, Fukabori R, Okada K, Uchigashima M, Watanabe M, Tsutsui Y, Kobayashi K (2011) Selective neural pathway targeting reveals key roles of thalamostriatal projection in the control of visual discrimination. J Neurosci 31:17169-17179
43. Kimura M, Minamimoto T, Matsumoto N, Hori Y (2004) Monitoring and switching of cortico-basal ganglia loop functions by the thalamo-striatal system. Neurosci Res 48:355-360
44. Kinomura S, Larsson J, Gulyas J, Roland PR (1996) Activation by attention of the human reticular formation and thalamic intralaminar nuclei. Science 271:512-515
45. Kliem MA, Pare JF, Khan ZU, Wichmann T, Smith Y (2009) Comparative ultrastructural analysis of D1 and D5 dopamine receptor distribution in the substantia nigra and globus pallidus of monkeys. Adv Behav Biol 58:239-253
46. Kurlan R, Kim MH, Gash DM (1991) Oral levodopa dose-response study in MPTP-induced hemiparkinsonian monkeys: assessment with a new rating scale for monkey parkinsonism. Mov Disord 6:111-118
47. Kusnoor SV, Parris J, Muly EC, Morgan JI, Deutch AY (2010) Extracerebellar role for Cerebellin 1: modulation of dendritic spine density and synapses in striatal medium spiny neurons. J Comp Neurol 518:2525-2537
48. Kusnoor SV, Bubser M, Deutch AY (2012) The effects of nigrostriatal dopamine depletion on the thalamic parafascicular nucleus. Brain Res 1446:46-55
49. Lanciego JL, Vazquez A (2012) The basal ganglia and thalamus of the long-tailed macaque in stereotaxic coordinates. A template atlas based on coronal, sagittal and horizontal brain sections. Brain Struct Funct 217:613-666
50. Levin BE, Katzen HL (2005) Early cognitive changes and nondementing behavioral abnormalities in Parkinson's disease. Adv Neurol 96:84-94
51. Liu C, Wang Y, Smallwood PM, Nathans J (2008) An essential role for Frizzled 5 in neuronal survival in the parafascicular nucleus of the thalamus. J Neurosci 28:5641-5653
52. Marien M, Briley M, Colpaert F (1993) Noradrenaline depletion exacerbates MPTP-induced striatal dopamine loss in mice. Eur J Pharmacol 236:487-489
53. Marini AM, Schwartz JP, Kopin IJ (1989) The neurotoxicity of 1-methyl-4-phenylpyridinium in cultured cerebellar granule cells. J Neurosci 9:3665-3672
54. Masilamoni G, Votaw J, Howell L, Villalba RM, Goodman M, Voll RJ, Stehouwer J, Wichmann T, Smith Y (2010) (18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol 226:265-273
55. Masilamoni GJ, Bogenpohl JW, Alagille D, Delevich K, Tamagnan G, Votaw JR, Wichmann T, Smith Y (2011) Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys. Brain 134:2057-2073
56. Matsumoto Y, Yoshida M, Watanabe S, Yamamoto T (2001) Involvement of cholinergic and glutamatergic functions in working memory impairment induced by interleukin-1 beta in rats. Eur J Pharmacol 430:283-288
57. Mennemeier M, Fennell E, Valenstein E, Heilman KM (1992) Contributions of the left intralaminar and medial thalamic nuclei to memory. Comparisons and report of a case. Arch Neurol 49:1050-1058
58. Mennemeier M, Crosson B, Williamson DJ, Nadeau SE, Fennell E, Valenstein E, Heilman KM (1997) Tapping, talking and the thalamus: possible influence of the intralaminar nuclei on basal ganglia function. Neuropsychologia 35:183-193
59. Muslimovic D, Post B, Speelman JD, Schmand B (2005) Cognitive profile of patients with newly diagnosed Parkinson disease. Neurology 65:1239-1245
60. Nanda B, Galvan A, Smith Y, Wichmann T (2009) Effects of stimulation of the centromedian nucleus of the thalamus on the activity of striatal cells in awake rhesus monkeys. Eur J Neurosci 29:588-598
61. Przedborski S, Jackson-Lewis V, Djaldetti R, Liberatore G, Vila M, Vukosavic S, Almer G (2000) The parkinsonian toxin MPTP: action and mechanism. Restor Neurol Neurosci 16:135-142
62. Raju DV, Shah DJ, Wright TM, Hall RA, Smith Y (2006) Differential synaptology of vGluT2-containing thalamostriatal afferents between the patch and matrix compartments in rats. J Comp Neurol 499:231-243
63. Raju DV, Ahern TH, Shah DJ, Wright TM, Standaert DG, Hall RA, Smith Y (2008) Differential synaptic plasticity of the corticostriatal and thalamostriatal systems in an MPTP-treated monkey model of parkinsonism. Eur J Neurosci 27:1647-1658
64. Rommelfanger KS, Weinshenker D (2007) Norepinephrine: the redheaded stepchild of Parkinson's disease. Biochem Pharmacol 74:177-190
65. Rommelfanger KS, Edwards GL, Freeman KG, Liles LC, Miller GW, Weinshenker D (2007) Norepinephrine loss produces more profound motor deficits than MPTP treatment in mice. Proc Natl Acad Sci USA 104:13804-13809
66. Sadikot AF, Rymar V (2009) The primate centromedian-parafascicular complex: anatomical organization with a note on neuromodulation. Brain Res Bull 78:122-130
67. Sadikot AF, Parent A, Francois C (1992) Efferent connections of the centromedian and parafascicular thalamic nuclei in the squirrel monkey: a PHA-L study of subcortical projections. J Comp Neurol 315:137-159
68. Schmitz C, Hof PR (2005) Design-based stereology in neuroscience. Neuroscience 130:813-831
69. Schneider JS (1990) Chronic exposure to low doses of MPTP. II. Neurochemical and pathological consequences in cognitively-impaired, motor asymptomatic monkeys. Brain Res 534:25-36
70. Schneider JS (2006) Modeling cognitive deficits associated with parkinsonism in chronic-low-dose MPTP-treated monkey. In: Levin ED, Buccafusco JJ, (eds) Animal models of cognitive impairment. CRC Press, Boca Raton, (Chapter 9, Frontiers in Neuroscience)
71. Schneider JS, Kovelowski CJ 2nd (1990) Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Res 519:122-128
72. Sedaghat K, Finkelstein DI, Gundlach AL (2009) Effect of unilateral lesion of the nigrostriatal dopamine pathway on survival and neurochemistry of parafascicular nucleus neurons in the rat-evaluation of time-course and LGR8 expression. Brain Res 1271:83-94
73. Shen PJ, Fu P, Phelan KD, Scott DJ, Layfield S, Tregear GW, Bathgate RA, Gundlach AL (2005) Restricted expression of LGR8 in intralaminar thalamic nuclei of rat brain suggests a role in sensorimotor systems. Ann NY Acad Sci USA 1041:510-515
74. Sidibe M, Smith Y (1996) Differential synaptic innervation of striatofugal neurones projecting to the internal or external segments of the globus pallidus by thalamic afferents in the squirrel monkey. J Comp Neurol 365:445-465
75. Sidibe M, Smith Y (1999) Thalamic inputs to striatal interneurons in monkeys: synaptic organization and co-localization of calcium binding proteins. Neuroscience 89:1189-1208
76. +), the toxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Toxicology 49:17-23
77. Slomianka L, West MJ (2005) Estimators of the precision of stereological estimates: an example based on the CA1 pyramidal cell layer of rats. Neuroscience 136:757-767
78. Smith Y, Bolam JP (1991) Convergence of synaptic inputs from the striatum and the globus pallidus onto identified nigrocollicular cells in the rat: a double anterograde labeling study. Neuroscience 44:45-73
79. Smith Y, Raju DV, Pare JF, Sidibe M (2004) The thalamostriatal system: a highly specific network of the basal ganglia circuitry. Trends Neurosci 27:520-527
80. Smith Y, Raju D, Nanda B, Pare JF, Galvan A, Wichmann T (2009) The thalamostriatal systems: anatomical and functional organization in normal and parkinsonian states. Brain Res Bull 78:60-68
81. Smith Y, Surmeier DJ, Redgrave P, Kimura M (2011) Thalamic contributions to basal ganglia-related behavioral switching and reinforcement. J Neurosci 31:16102-16106
82. Soares J, Kliem MA, Betarbet R, Greenamyre JT, Yamamoto B, Wichmann T (2004) Role of external pallidal segment in primate parkinsonism: comparison of the effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism and lesions of the external pallidal segment. J Neurosci 24:6417-6426
83. Storey E, Hyman BT, Jenkins B, Brouillet E, Miller JM, Rosen BR, Beal MF (1992) 1-Methyl-4-phenylpyridinium produces excitotoxic lesions in rat striatum as a result of impairment of oxidative metabolism. J Neurochem 58:1975-1978
84. Villalba RM, Smith Y (2011) Differential structural plasticity of corticostriatal and thalamostriatal axo-spinous synapses in MPTP-treated Parkinsonian monkeys. J Comp Neurol 519:989-1005
85. Villalba RM, Raju DV, Hall RA, Smith Y (2006) GABA(B) receptors in the centromedian/parafascicular thalamic nuclear complex: an ultrastructural analysis of GABA(B)R1 and GABA(B)R2 in the monkey thalamus. J Comp Neurol 496:269-287
86. Villalba RM, Lee H, Smith Y (2009) Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Exp Neurol 215:220-227
87. Villalba RM, Wichmann T, Smith Y (2011) Neuronal loss in the caudal intralaminar nuclear group, CM/Pf, in MPTP-treated parkinsonian monkeys. Society for Neuroscience (Abstracts)
88. Villalba RM, Wichmann T, Smith Y (2012) Early neuronal loss in the centre median and parafascicular thalamic nuclei prior to the development of parkinsonian motor symptoms in MPTP-treated monkeys. Society for Neuroscience (Abstracts)
89. Watanabe Y, Himeda T, Araki T (2005) Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med Sci Monit 11:RA17-RA23
90. West MJ (1999) Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci 22:51-61
91. West MJ, Slomianka L, Gundersen HJ (1991) Unbiased stereological estimation of the total number of neurons in the subdivisions of the rat hippocampus using the optical fractionator. Anat Rec 231:482-497
92. Wichmann T, Soares J (2006) Neuronal firing before and after burst discharges in the monkey basal ganglia is predictably patterned in the normal state and altered in parkinsonism. J Neurophysiol 95:2120-2133
93. Wichmann T, Kliem MA, DeLong MR (2001) Antiparkinsonian and behavioral effects of inactivation of the substantia nigra pars reticulata in hemiparkinsonian primates. Exp Neurol 167:410-424
94. Williams-Gray CH, Foltynie T, Lewis SJ, Barker RA (2006) Cognitive deficits and psychosis in Parkinson's disease: a review of pathophysiology and therapeutic options. CNS Drugs 20:477-505
95. Xuereb JH, Perry RH, Candy JM, Perry EK, Marshall E, Bonham JR (1991) Nerve cell loss in the thalamus in Alzheimer's disease and Parkinson's disease. Brain 114:1363-1379
96. Zackheim J, Abercrombie ED (2005) Thalamic regulation of striatal acetylcholine efflux is both direct and indirect and qualitatively altered in the dopamine-depleted striatum. Neuroscience 131:423-436